All posts by: Michael Zand

Combination immunotherapy, chemotherapy feasible in metastatic bladder cancer – Healio

Combination immunotherapy, chemotherapy feasible in metastatic bladder cancerHealio“Because chemotherapy and immunotherapy are the two pillars of treatment for metastatic bladder cancer, we sought to better understand how these treatments might be best… Continue reading

Trial ‘Desperately Needed’ to Sequence Immunotherapy and Chemo in Lung Cancer – Medscape

Dr. Harshman on Earlier Use of Immunotherapy in RCC – OncLive

OncLiveDr. Harshman on Earlier Use of Immunotherapy in RCCOncLiveHarshman says that the next step in the treatment of patients with RCC is moving immunotherapy into earlier lines of treatment. Investigators are currently testing checkpoint inhibitors s… Continue reading

CAR T-Cell Therapy, Checkpoint Inhibitors Making Waves Across Hematologic Malignancies – OncLive

OncLiveCAR T-Cell Therapy, Checkpoint Inhibitors Making Waves Across Hematologic MalignanciesOncLiveIn addition to CAR T-cell therapies, checkpoint inhibition is also an area that investigators are focusing on in various lymphoma subtypes, said Younes,… Continue reading

MPS IIIA Gene Therapy, ABO-102, Shows Efficacy in Trial Update – Rare Disease Report

Voice Of AnalystsMPS IIIA Gene Therapy, ABO-102, Shows Efficacy in Trial UpdateRare Disease ReportThis morning, Abeona Therapeutics Inc. released positive data from its phase 1/2 trial for ABO-102 (AAV-SGSH), a clinical gene therapy for the treatment o… Continue reading

MPS IIIA Gene Therapy, ABO-102, Shows Efficacy in Trial Update – Rare Disease Report

Voice Of AnalystsMPS IIIA Gene Therapy, ABO-102, Shows Efficacy in Trial UpdateRare Disease ReportThis morning, Abeona Therapeutics Inc. released positive data from its phase 1/2 trial for ABO-102 (AAV-SGSH), a clinical gene therapy for the treatment o… Continue reading